

1 **Bad company? The pericardium microbiome in people investigated for tuberculosis**  
2 **pericarditis in an HIV-prevalent setting**

3

4 Georgina Nyawo<sup>1,2†</sup>, Charissa Naidoo<sup>1,2†</sup>, Benjamin G. Wu<sup>3,4</sup>, Benjamin Kwok<sup>3</sup>, Jose C.  
5 Clemente<sup>5</sup>, Yonghua Li<sup>3</sup>, Stephanie Minnies<sup>1</sup>, Byron Reeve<sup>1</sup>, Suventha Moodley<sup>1,2</sup>,  
6 Thadathilankal-Jess John<sup>6,7</sup>, Sumanth Karamchand<sup>7</sup>, Shivani Singh<sup>3</sup>, Alfonso Pecararo<sup>7</sup>,  
7 Anton Doubell<sup>7</sup>, Charles Kyriakakis<sup>8</sup>, Robin Warren<sup>1</sup>, Leopoldo N. Segal<sup>3</sup>, Grant Theron<sup>1,2#</sup>

8 †Contributed equally

9

10 **Running title:** Pericardium microbiome in tuberculosis

11

12 **Affiliations:**

13 <sup>1</sup>DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research; South African  
14 Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology  
15 and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University,  
16 Cape Town, South Africa;

17 <sup>2</sup>African Microbiome Institute, Faculty of Medicine and Health Sciences, Stellenbosch  
18 University, Cape Town, South Africa;

19 <sup>3</sup>Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, New  
20 York University School of Medicine, New York, USA;

21 <sup>4</sup>Division of Pulmonary and Critical Care, Veterans Affairs New York Harbor Healthcare  
22 System, New York, NY, USA;

23 <sup>5</sup>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai,  
24 New York, USA;

25 <sup>6</sup>Panorama Mediclinic, Cape Town, South Africa;

26 <sup>7</sup>Department of Medicine, Division of Cardiology, Stellenbosch University & Tygerberg  
27 Academic Hospital, Cape Town, South Africa;

28 <sup>8</sup>Life Vincent Pallotti Hospital, Cape Town, South Africa.

29

30 **#Corresponding author:**

31 Professor Grant Theron, 2<sup>nd</sup> Floor BMRI Building, Division of Molecular Biology and Human  
32 Genetics, Faculty of Medicine and Health Sciences, Francie Van Zijl Drive, Tygerberg, South  
33 Africa, 7505.

34 E-mail: [gtheron@sun.ac.za](mailto:gtheron@sun.ac.za)

35 Telephone: +27 21 938 9693

36

37 **Keywords:** pericarditis, extrapulmonary tuberculosis, microbiome, HIV

38 **Abstract**

39 **Background:** The microbiome likely plays a role in tuberculosis (TB) pathogenesis. We  
40 evaluated the site-of-disease microbiome and predicted metagenome in people with  
41 presumptive tuberculous pericarditis, a major cause of mortality, and explored for the first  
42 time, the interaction between its association with C-reactive protein (CRP), a potential  
43 diagnostic biomarker and the site-of-disease microbiome in extrapulmonary TB.

44 **Methods:** People with effusions requiring diagnostic pericardiocentesis (n=139) provided  
45 background sampling controls and pericardial fluid (PF) for 16S rRNA gene sequencing  
46 analysed using QIIME2 and PICRUSt2. Blood was collected to measure CRP.

47 **Results:** PF from people with definite (dTb, n=91), probable (pTB, n=25), and non- (nTB,  
48 n=23) tuberculous pericarditis differed in  $\beta$ -diversity. dTBs were, vs. nTBs, *Mycobacterium*-,  
49 *Lacticigenium*-, and *Kocuria*-enriched. Within dTBs, HIV-positives were *Mycobacterium*-,  
50 *Bifidobacterium*-, *Methylobacterium*-, and *Leptothrix*-enriched vs. HIV-negatives and HIV-  
51 positive dTBs on ART were *Mycobacterium*- and *Bifidobacterium*-depleted vs. those not on  
52 ART. Compared to nTBs, dTBs exhibited short-chain fatty acid (SCFA) and mycobacterial  
53 metabolism microbial pathway enrichment. People with additional non-pericardial  
54 involvement had differentially PF taxa (e.g., *Mycobacterium*-enrichment and *Streptococcus*-  
55 depletion associated with pulmonary infiltrates). *Mycobacterium* reads were in 34% (31/91),  
56 8% (2/25) and 17% (4/23) of dTBs, pTBs, and nTBs, respectively.  $\beta$ -diversity differed  
57 between patients with CRP above vs. below the median value (*Pseudomonas*-depleted).  
58 There was no correlation between enriched taxa in dTBs and CRP.

59 **Conclusions:** PF is compositionally distinct based on TB status, HIV (and ART) status and  
60 dTBs are enriched in SCFA-associated taxa. The clinical significance of these findings,  
61 including mycobacterial reads in nTBs and pTBs, requires evaluation.

## 62 Introduction

63 The burden of tuberculosis (TB) is severe in sub-Saharan Africa, where HIV is frequent<sup>1</sup>. In  
64 2021, South Africa reported >300 000 incident TB cases and 61 000 deaths<sup>1</sup>. About 16% of  
65 incident cases are extrapulmonary, affecting sites outside the lungs<sup>2</sup>. Extrapulmonary TB  
66 (EPTB) has high fatality, especially in people living with HIV (PLHIV)<sup>3</sup>. Tuberculous  
67 pericarditis (TBP) is an especially severe manifestation, and the deadliest manifestation of  
68 EPTB, with up to 40% mortality<sup>4-6</sup>.

69

70 Immune responses to *Mycobacterium tuberculosis* complex (*Mtb*) involve a cascade of  
71 events that are, in part, influenced by the microbiome and their metabolites<sup>7 8</sup>. For instance,  
72 gut enrichment with specific anaerobes (*Anaerostipes*, *Blautia*, *Erysipelotrichaceae*)  
73 independently predicts activation of host inflammatory immune pathways and active  
74 pulmonary TB compared to sick controls<sup>9 10</sup>. In PLHIV on ART, greater microbially-derived  
75 short chain fatty acid (SCFA; butyrate, propionate) concentrations in the lower airways  
76 independently predict incident TB<sup>11</sup>. When SCFAs are added at physiological  
77 concentrations to alveolar macrophages *ex vivo*, there are reductions in macrophage-  
78 mediated *Mtb* kill<sup>11</sup>.

79

80 C-reactive protein (CRP) is a non-specific blood inflammatory marker for triage<sup>12</sup>, especially  
81 in PLHIV in primary care, where it is WHO-recommended<sup>13</sup>. In studies where CRP was co-  
82 analysed with the microbiome, CRP negatively correlated with abundances of anti-  
83 inflammatory-associated gut microbiota<sup>14</sup> such as *Faecalibacterium*<sup>15</sup>, *Lactobacillus* and  
84 *Bifidobacterium*<sup>16</sup>. In COVID-19 patients, CRP correlated with potentially pathogenic bacteria  
85 such as *Klebsiella* spp. and *Enterococcus* spp.<sup>17</sup> However, the relationship between CRP  
86 and the site-of-disease microbiota in presumptive TBP has not been studied.

87

88 Little is known about the microbiome of the pericardial space, especially in the context of  
89 EPTB, a major cause of pericardial disease. Previous research has hinted at the influence of

90 microbiota on TB, making it a promising treatment avenue<sup>7-9</sup>. Our work showed the presence  
91 of distinctive microbial communities at the site of disease in people with presumptive  
92 tuberculous lymphadenitis<sup>18</sup>. Importantly, these communities differed by TB status (definite-,  
93 probable- or non-TB) and clinical characteristics, with specific community states (i.e.,  
94 *Mycobacterium*-dominated lymphotype) being associated with more severe disease<sup>18</sup>.

95

96 Together, this can aid in the identification of novel biomarkers at the microbial-host interface  
97 that leads to strategies like host-directed therapies for TB prevention and treatment,  
98 including in PLHIV. This could also enhance our understanding of severe inflammation in  
99 EPTB, which partly contributes to its high morbidity and mortality. Understanding interactions  
100 in the microbiome, together with correlations with CRP can help find meaningful networks via  
101 which microbes and host interact, and this can help uncover novel associations and  
102 mechanisms.

103

104 We therefore evaluated the site-of-disease microbiome and its predicted metagenome in  
105 people investigated for TBP (including PLHIV) as well as whether CRP as a surrogate for  
106 inflammation correlates with specific taxa. This work will help provide foundational data on  
107 the microbiome's role in TBP.

108 **Methods**

109 *Recruitment and follow-up*

110 People with presumed TB pericarditis referred to Tygerberg Academic Hospital in Cape  
111 Town, South Africa for routine diagnostic investigation including pericardiocentesis were  
112 recruited between 24 November 2016 and 9 April 2021. Eligible people were  $\geq 18$  years old  
113 and not on TB treatment for  $\geq 2$  weeks. Demographic, clinical, and chest X-ray (CXR) data  
114 were collected. People with TBP were managed by the overseeing clinician in line with  
115 current guidelines for the management and treatment of pericardial effusions, and assessed  
116 by telephonic follow-up after a minimum of 12 weeks. The study had no role in patient  
117 management.

118

119 *Ethics*

120 All people provided written informed consent. The study was approved by the Stellenbosch  
121 University Health Research and Ethical Committee (HREC, N16/04/050), Tygerberg  
122 Academic Hospital, and the Western Cape Department of Health (WC\_2016RP15\_762).

123

124 *Specimen collection and processing*

125 Two sampling controls were collected per person: a skin swab of the sterilised puncture site  
126 and a sterile saline (Ysterplaat Medical Supplies, South Africa) flush of the vascular sheath  
127 prior to pericardiocentesis (background control). At least 4mL pericardial fluid (PF) was  
128 collected once sufficient volumes were obtained for routine diagnostic testing. Samples were  
129 stored at  $-80^{\circ}\text{C}$  until batched DNA extraction. Peripheral blood was collected in serum-  
130 separating tubes (SST tubes; BD), and centrifuged ( $2054g$ ,  $10\text{ min}$ ) within four hours of  
131 collection, and serum stored at  $-80^{\circ}\text{C}$ . Further details on specimen collection and  
132 microbiological testing is in the **Supplementary material**.

133

134 *Patient classification*

135 We designated people as definite tuberculous pericarditis (dTb), probable tuberculous  
136 pericarditis (pTb), or non-tuberculous pericarditis (nTb) per **Table S1**<sup>19</sup>. People were  
137 classified as dTbs if they were positive for acid-fast bacilli by Ziehl-Neelsen smear  
138 microscopy and/or had at least one MTB-positive specimen by Mycobacteria Growth  
139 Indicator Tube (MGIT) 960 liquid culture (BD Diagnostics, USA), Xpert MTB/RIF (Xpert;  
140 Cepheid, USA) and/or Xpert MTB/RIF Ultra (Ultra; Cepheid, USA). pTbs did not meet dTb  
141 criteria, had no alternative diagnosis, and were empirically prescribed TB therapy. nTbs had  
142 no microbiological evidence of TB and were not placed on treatment.

143

#### 144 *Laboratory procedures*

145 The PureLink Microbiome DNA Purification Kit (Invitrogen, USA) was used for PF, skin  
146 swabs and, for efficiency, 1 in 5 background samples. The 16S rRNA gene V4 hypervariable  
147 region (150 bp read length, paired-end) was amplified and underwent Illumina MiSeq  
148 sequencing<sup>11</sup>. Further detail is in the **Supplementary Material**. CRP was measured in bio-  
149 banked serum using the Cobas High-Sensitivity Immunoturbidimetric Assay (Roche  
150 Diagnostics Limited, Burgess Hill, UK) per the manufacturer's [instructions](#).

151

#### 152 *Microbiota analyses*

153 Pre-processing: Sequences were pre-processed using QIIME (version 2020.8)<sup>20</sup> and  
154 DADA2<sup>21</sup>. Amplicon sequence variants (ASVs) were assigned at 99% similarity against  
155 representative sequences in Greengenes (version 13.8)<sup>22</sup> with zero abundance taxa  
156 removed.

157 Taxonomic analyses:  $\alpha$ - and  $\beta$ -diversities were calculated using *vegan* (v2.6-4)<sup>23</sup>.  
158 Differential taxa and pathway abundance analyses used *DESeq2* (v1.22.2)<sup>24</sup> with Benjamini-  
159 Hochberg (BH) multiple testing correction after feature tables were pruned (genera not seen  
160 >5 times in  $\geq 1\%$  of samples removed)<sup>25</sup>. CRP was categorised as high or low if the  
161 concentration readout was above or below the median for the people included in that

162 analysis. Detailed methods for identifying potential contaminants and clustering analysis are  
163 in the **Supplementary Material**.

164 Functional pathway analyses: Phylogenetic Investigation of Communities by  
165 Reconstruction of Unobserved States (PICRUSt2; v.2.1.3-b)<sup>26</sup> was used for metagenomic  
166 inference with default parameters (picrust2\_pipeline.py) and metabolic function predictions  
167 based on MetaCyc<sup>27</sup>.

168 Correlation analysis with CRP and microbiome: Only sequence data with paired CRP  
169 measurements were included. Microbial relative abundances were correlated with CRP  
170 measurements using Correlations Under the Influence (CUTIE)<sup>28</sup>.

171

#### 172 *Statistical analyses*

173 Analyses used GraphPad Prism (v7; GraphPad Software, USA), STATA (v16; StataCorp,  
174 USA) and R (v4.2; R Core Team). Medians with interquartile ranges (IQRs) were reported  
175 for continuous variables, and the number and percentage were reported for categorical  
176 variables. Non-parametric tests (microbiome data are not normally distributed<sup>29</sup>) included the  
177 Mann-Whitney or Wilcoxon signed-rank test for unpaired and paired comparisons involving  
178 two groups, Kruskal-Wallis or Friedman tests for unpaired and paired comparisons involving  
179  $\geq 2$  groups, and Spearman's Rho for correlation analyses. Permutational multivariate analysis  
180 of variance (PERMANOVA) was computed with 999 permutations for  $\beta$ -diversity, and  $R^2$   
181 used to measure variation explained by a variable. The Benjamini–Hochberg procedure was  
182 used to correct for multiple comparisons by controlling the false discovery rate (FDR)<sup>25</sup>.  
183 Adjusted  $p$ -values of  $<0.2$  and  $<0.05$  were considered significant for taxa and pathways,  
184 respectively<sup>30</sup>. More information is in the **Supplementary Methods**.



## 185 **Results**

### 186 *Cohort characteristics*

187 Our cohort was comprised of 91 (65%), 25 (18%) and 23 (17%) dTBs, pTBs, and nTBs,  
188 respectively (**Table 1**). Compared to nTBs, dTBs were more likely to have HIV, cough,  
189 weight loss, be on medication (other than TB medication) and, in their PF, have lower  
190 albumin but higher adenosine deaminase (ADA), lactate dehydrogenase (LDH), and  
191 unstimulated interferon-gamma (uIFN- $\gamma$ ) concentrations. pTBs were more likely than nTBs to  
192 have HIV, previous TB, and TB symptoms and, in PF, lower albumin and higher ADA and  
193 uIFN- $\gamma$  concentrations.

194

### 195 *Pericardial fluid shares few taxa with skin and background controls*

196 PF  $\alpha$ -diversity was lower than background and skin. PF  $\beta$ -diversity differences occurred with  
197 *Mycobacterium*- (vs. skin and background) and *Streptococcus*-enrichment (vs. skin only)  
198 (**Figure S1A-D**). None of the top four potentially contaminating taxa identified appeared in  
199 differential analyses (**Figures S2-3**, [additional table](#)).

200

### 201 *Mycobacterium and other potential opportunistic pathogens are enriched in dTBs*

202 Differences by TB status: We did not detect  $\alpha$ -diversity differences (**Figure 2A**).  $\beta$ -  
203 diversity differed between dTBs and pTBs, as well as pTBs vs. nTBs (PERMANOVA  
204  $p=0.020$  and  $0.003$ , respectively, **Figure 2B**), but not between dTBs and nTBs. dTBs were  
205 *Mycobacterium*-, *Lacticigenium*-, and *Kocuria*-enriched vs. nTBs (**Figure 2C**), and  
206 *Mycobacterium*-, *Lacticigenium*- and *Caulobacter*-enriched and *Streptococcus*-depleted vs.  
207 pTBs (**Figure 2D**). pTBs were *Streptococcus*- (vs. dTBs) and *Novosphingobium*-enriched vs.  
208 nTBs (**Figure 2D-E**), and more phylogenetically dissimilar to each other. dTBs were the  
209 most phylogenetically similar to each other followed by nTBs (**Figure S4**).

210 Grouping pTBs with dTBs or nTBs: When pTBs were grouped with dTBs or nTBs,  
211 there were no  $\alpha$ - or  $\beta$ -diversity differences vs. nTBs or dTBs, respectively (**Figure S5A-D**).

212 dTBs were *Mycobacterium*- and *Lacticigenium*-enriched vs. nTBs regardless of with whom  
213 pTBs were grouped (**Figure S5E-F**).

214 16S rRNA gene sequencing correlates with diagnostic results: Mycobacterial reads  
215 occurred in more dTBs than pTBs [34% (31/91) vs. 8% (2/25),  $p=0.011$ ] but did not reach  
216 significance when dTBs were compared to nTBs [17% (4/23),  $p=0.181$ ] (**Figure 2F, Figure**  
217 **S6**). Mycobacterial reads inversely correlated with PCR ( $r=-0.361$ ,  $p<0.012$ ; **Figure S7A**)  
218 and culture measures of mycobacterial load ( $r=-0.484$ ,  $p<0.001$ ; **Figure S7B**).

219

220 *Bifidobacterium* enrichment is associated with HIV

221 Although  $\alpha$ - and  $\beta$ -diversity did not differ by HIV status (**Figure S8A-B**), PLHIV were  
222 *Mycobacterium*-enriched vs. HIV-negatives (**Figure S8C**).

223 Comparisons by HIV status within different TB groups: No  $\alpha$ - and  $\beta$ -diversity  
224 differences by HIV status occurred in dTBs or pTBs (**Table S2**). In dTBs, HIV-positives were  
225 *Methylobacterium*-, *Bifidobacterium*-, and *Leptothrix*-enriched vs. HIV-negatives (**Figure**  
226 **S8D**). nTBs were not compared by HIV status due to a small sample size (n=2 HIV-  
227 positives).

228 Comparisons by TB status within people of the same HIV status: In HIV-positives,  $\alpha$ -  
229 diversity was similar by TB status (**Figure 3A**) but  $\beta$ -diversity differed ( $p=0.038$ ; **Figure 3B**)  
230 and dTBs were *Mycobacterium*-, *Bifidobacterium*-, and *Leptothrix*-enriched vs. pTBs (**Figure**  
231 **3C**).  $\alpha$ - and  $\beta$ -diversities were similar between HIV-positives with high vs. low CD4 counts  
232 (dichotomised at median value, data not shown), where those with lower counts were  
233 *Mycobacterium*-enriched vs. people with higher counts (**Figure S9A-B**). In HIV-negatives,  $\alpha$ -  
234 and  $\beta$ -diversities were similar between TB groups (**Figure 3D-E**) and taxonomic differences  
235 were only observed between dTBs vs. pTBs, with dTBs *Kocuria*-, *Halomonas*-, and  
236 *Gilvimirinus*-enriched (**Figure 3F**).

237 Comparisons by ART status in PLHIV: A third of PLHIV were on ART (**Table 1**).  $\alpha$ -  
238 Diversity was similar by ART status, but  $\beta$ -diversity differed (**Table S2**). Those on ART were

239 *Streptococcus*-enriched and *Mycobacterium*- and *Bifidobacterium*-depleted vs. those not on  
240 ART (**Figure S9C**) and conclusions were similar when restricted to dTBs (**Figure S9D**).

241

242 *Chest abnormalities associated with the microbiome.*

243 We evaluated microbiome differences by CXR results (**Table 1**) and found no  $\alpha$ -diversity  
244 differences. However,  $\beta$ -diversity differed in people with vs. without pulmonary infiltrates  
245 (PIs; **Table S2**), with people with PIs *Mycobacterium*-enriched and *Streptococcus*-depleted  
246 (**Figure 4A**).  $\beta$ -diversity also differed in people with or without pleural effusions (PEs) (**Table**  
247 **S2**), where people with PEs were *Streptococcus*- and *Pseudomonas*-enriched and  
248 *Brachymonas*-depleted (**Figure 4B**).

249

250 *People with definite TBP are enriched in SCFA metabolic pathways.*

251 Compared to nTBs, dTBs were enriched with SCFA metabolism (*L-lysine fermentation to*  
252 *acetate and butanoate*), aromatic compound degradation (*cinnamate and 3-*  
253 *hydroxycinnamate degradation to 2-oxopent-4-enoate*), and mycobacterial metabolism  
254 (*superpathway of mycolyl-arabinogalactan-peptidoglycan complex biosynthesis*) pathways  
255 (**Figure 5**). Amongst dTBs, HIV-positives were depleted in biosynthesis pathways [*GDP-D-*  
256 *glycero- $\alpha$ -D-manno-heptose biosynthesis*, *peptidoglycan biosynthesis V ( $\beta$ -lactam*  
257 *resistance)* and *superpathway of geranylgeranyl diphosphate biosynthesis II (via MEP)*]  
258 compared to HIV-negatives (**Figure S10**). Comparisons involving pTBs are in **Figures S11-**  
259 **S12**.

260

261 *The association between CRP and the microbiome*

262 Microbial composition differed with *Pseudomonas* depleted in high vs. low CRP

263 CRP concentrations did not differ by TB status [median 137.30 (IQR 75.30 - 176.30) ng/mL  
264 in dTBs vs. 95.96 (IQR 45.25 - 173.70) ng/mL in nTBs] (**Figure 6A**) nor correlated with  
265 *Mycobacterium* reads (**Figure 6B-C**). People with above median CRP concentrations  
266 [median 125.4 (IQR70.83 – 176.7) ng/mL] had, vs. those below the median, no  $\alpha$ -diversity

267 differences (**Figure 6D**) but different  $\beta$ -diversity (**Figure 6E**), with *Pseudomonas*-depletion  
268 (**Figure 6F**). These differences were similar when restricted to people of a specific TB  
269 (**Table 2**) or HIV status (**Figures S13-14**), with a few additional taxa differentially enriched.  
270 The top three taxa enriched in dTBs (*Mycobacterium*, *Lacticigenium*, *Kocuria*) did not  
271 correlate with CRP levels (p-values of 0.523, 0.260, and 0.999, respectively).

## 272 Discussion

273 Our key findings are that 1) compared to PF from people without TBP, PF from people with  
274 TBP differs both in terms of  $\beta$ -diversity and the relative abundance of specific taxa, including  
275 those other than *Mycobacterium* (*Lacticigenium*, *Kocuria*, and *Weeksella*), 2) HIV is  
276 associated with the differential abundance of *Mycobacterium* overall, and within dTBs,  
277 *Bifidobacterium* is associated with proxies of more severe disease (HIV-positivity and, in  
278 PLHIV, no ART), and 3) taxonomic differences between dTBs and nTBs manifest in different  
279 functional capacities, including enrichment of SCFA production pathways. Furthermore, 4)  
280 the PF microbiome is associated with distinctive clinical and chest imaging characteristics  
281 and 5) many people with dTB do not have PF *Mycobacterium* reads whereas some people  
282 without dTB have *Mycobacterium* reads, 6) CRP did not differ by TB status or HIV status,  
283 and  $\alpha$ -diversity was similar by CRP status, however,  $\beta$ -diversity differed, with *Pseudomonas*  
284 enrichment in people with low (vs. high) CRP. This is the first characterisations of the site-of-  
285 disease microbiome in people with pericarditis, specifically in a high TB HIV-endemic setting.

286

287 dTBs were enriched in several taxa in addition to *Mycobacterium*. These include *Kocuria*, a  
288 skin commensal that causes an infection of the heart e.g., native valve endocarditis, albeit  
289 rarely<sup>31</sup>, and *Weeksella* which can also cause serious bacterial infections like bacteraemia,  
290 and spontaneous bacterial peritonitis<sup>32</sup>. The relevance of these taxa in TBP requires further  
291 investigation.

292

293 *Mycobacterium* was enriched in PLHIV compared to people without HIV. Furthermore,  
294 *Bifidobacterium* was associated with clinical features characteristic of severe disease (HIV-  
295 positivity and, in those with HIV, no ART and lower CD4 counts. *Bifidobacterium*, while  
296 commonly considered a beneficial, immunomodulatory gut commensal<sup>33</sup>, has been  
297 described as either depleted<sup>9 34</sup> or enriched<sup>35 36</sup> in people with pulmonary TB compared to  
298 symptomatic controls. However, our findings are consistent with the latter. *Bifidobacterium*

299 can act opportunistically, causing bacteraemia in immunocompromised people and those  
300 with a damaged intestinal barrier<sup>37</sup>.

301

302 Similar to previous work involving people with different forms of TB (i.e., pulmonary TB and  
303 TB lymphadenitis<sup>38</sup>), people with TBP were enriched in SCFA-producing bacteria (e.g.,  
304 *Lacticigenium* produces acetic and lactic acid) and pathways (*L-lysine fermentation to*  
305 *acetate and butanoate*, amino acid and carbohydrate metabolism butyrate precursor  
306 pathways)<sup>39 40</sup>. dTBs also had elevated PF concentrations of LDH, a marker of tissue  
307 damage, however we acknowledge that it could include microbially-derived LDH. Lactate  
308 metabolism is also important for *Mtb* growth<sup>41</sup>

309

310 Furthermore, HIV-positive dTBs not on ART are, in addition to *Mycobacterium*, enriched in  
311 *Bifidobacterium*, a known producer of lactate which itself is also an intermediate metabolite  
312 of the butyrate biosynthetic pathway<sup>42 43</sup>. Butyrate suppresses protective host responses  
313 (IFN- $\gamma$  and IL-17A) to *Mtb*. Future studies should evaluate whether enhanced site-of-disease  
314 SCFA production correlates with both local and peripheral inflammation.

315

316 Pericarditis is often associated with pulmonary parenchymal disease. Notably, the PF  
317 microbiome was associated with a greater probability of chest imaging characteristics where  
318 individuals with PI showed distinct PF  $\beta$ -diversity compared to those without, characterized  
319 by increased *Mycobacterium* (likely resulting from more direct contact with the route of  
320 infection and site of pulmonary disease) and reduced *Streptococcus*. Similarly, individuals  
321 with pleural effusion exhibited different PF  $\beta$ -diversity compared to those without, with higher  
322 levels of *Streptococcus* and lower levels of *Brachyomonas*. Pulmonary infiltrates are  
323 commonly observed in radiological imaging of individuals with pulmonary TB<sup>44</sup>, while pleural  
324 effusions are predominantly caused by TB in developing countries<sup>45</sup>. Consequently,  
325 obtaining sputum cultures and Xpert tests is crucial in suspected cases of TBP, even when  
326 parenchymal involvement is not evident. Furthermore, the co-existence of these features

327 may reflect the TB route from the lungs to the heart, and what taxa might accompany that  
328 spread.

329

330 People within each TB group had *Mtb* DNA detected. The reasons for this are likely  
331 multifaceted: primarily due to technical methodological limitations (metagenomic sequencing  
332 would have more discriminatory power for species within *Mycobacteria*) but could also be  
333 due to TB exposure, past infection, TB disease at another anatomical site, or cross-  
334 contamination. It is important to note that 66% of dTBs did not show *Mycobacterium*  
335 readings, likely due to the limited sensitivity of 16S rRNA sequencing for detecting this  
336 genus, whose cells often lyse and release DNA inefficiently and may be biased against by  
337 conventional sequencing approaches (a “mycobacteriome” approach could be used to study  
338 mycobacterial diversity further)<sup>46</sup>.

339

340 CRP is a commonly studied biomarker in TB, and during active TB infection, CRP levels  
341 tend to be elevated due to the body's immune response to the mycobacterial infection<sup>47</sup>.  
342 Similarly, CRP levels can be elevated in individuals with HIV because HIV infection is  
343 associated with chronic inflammation and immune activation, particularly in those with  
344 advanced disease or opportunistic infections<sup>48-50</sup>. However, in our study, unlike previously  
345 reported studies<sup>51-53</sup>, the level of CRP, appears to not be influenced by the presence of  
346 active TB in TBP. Despite this, the median CRP value in our TBP cohort 125.4 (70.83 –  
347 176.70) ng/mL exceeded the diagnostic threshold<sup>54</sup> for TB diagnosis. This observation can  
348 be attributed to the fact our study only included people that were suspected to have TPB,  
349 leading to the presence of specific clinical symptoms and some form of the disease,  
350 regardless of whether it was TB or another condition. As a result, this could have contributed  
351 to the elevated CRP levels to some extent. Notably, we observed a depletion of  
352 *Pseudomonas* in presumptive TBP people with high CRP compared to those with low CRP,  
353 similar to a report of an adverse relationship between sputum genus richness and CRP in  
354 bronchiectasis<sup>55 56</sup>.

355

356 The study has strengths and limitations. DNA-based sequencing was employed to analyze  
357 microbial communities, and alternative methods like culturomics, metagenomics, or  
358 metatranscriptomics may yield different results. Furthermore, as our study was nested within  
359 TB care at our hospital, our study data were influenced by limitations in routinely available  
360 data (e.g., unknown ART duration); however, this allowed us to recruit a high number of  
361 people. We also did background sampling and sequencing to detect potential cross-  
362 contamination of our low biomass fluid (PF), which allowed us to confirm that none of the  
363 discriminatory taxa identified in our analyses likely resulted from contamination. The study  
364 used a relaxed FDR-adjusted p-value threshold of 0.2 to identify various taxa, prioritizing  
365 hypothesis generation. This threshold was chosen as lower thresholds did not yield  
366 significant taxa, underscoring the need for broader exploration. We do not know which  
367 microbes are driving the high CRP in TB, however, this study was not designed to  
368 investigate this, and further studies would be required. We acknowledge the non-specificity  
369 of CRP as a general marker of inflammation. Finally, this study is a cross-sectional study, so  
370 it's unable to establish temporal relationships.

371

372 In summary, the microbiomes of people with TBP (including those co-infected with HIV) are  
373 different to people without TBP and characterised by enriched *Mycobacterium* and other  
374 potentially immunomodulatory bacteria (*Bifidobacterium*, *Lacticigenium*). Further research is  
375 needed to define these mechanistic relationships (e.g., through murine models), including  
376 how the microbiota is altered by treatment and its association, if any, with clinical outcomes.  
377 This will provide insights into the development of effective host-directed therapies for TBP.



## 378 **Funding**

379 This work and authors were supported by the European & Developing Countries Clinical  
380 Trials Partnership (EDCTP; project numbers SF1041, TMA2019CDF-2738-ESKAPE-TB),  
381 National Research Foundation, South African Medical Research Council (SAMRC), Harry  
382 Crossley Foundation and Stellenbosch University Faculty of Health Sciences. We also  
383 acknowledge funding from Veterans Affairs (IK2BX005309-01A2) and the National Institutes  
384 of Health under award number KL2TR001446, and CHEST Foundation Research Grant in  
385 Chronic Obstructive Pulmonary Disease. CCN and GT acknowledge funding from the  
386 National Institutes of Health under award numbers K43TW012302 and R01AI136894. GRN  
387 acknowledges funding from L'Oréal-UNESCO For Women in Science Sub-Saharan Africa  
388 Young Talents Award, and the International Rising Talents Award. The content is the solely  
389 the responsibility of the authors and does not necessarily represent the official views of the  
390 funders.

391

## 392 **Acknowledgments**

393 The authors thank all study participants and CLIME staff, especially Sr Ruth Wilson.  
394 Computations were performed using facilities provided by the University of Cape Town's  
395 ICTS High Performance Computing team: [hpc.uct.ac.za](http://hpc.uct.ac.za).

396

## 397 **Conflict of Interest**

398 The other authors each declare no competing interests.

399

## 400 **References**

- 401 1. World Health Organization. Global Tuberculosis Report 2022. Geneva, Switzerland, 2022.
- 402 2. Gupta RK, Lawn SD, Bekker L-G, et al. Impact of human immunodeficiency virus and  
403 CD4 count on tuberculosis diagnosis: analysis of city-wide data from Cape Town, South  
404 Africa. *The international journal of tuberculosis and lung disease* 2013;17(8):1014-22.

- 405 3. Leeds IL, Magee MJ, Kurbatova EV, et al. Site of extrapulmonary tuberculosis is  
406 associated with HIV infection. *2012*;55(1):75-81.
- 407 4. Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. *Circulation*  
408 2005;112(23):3608-16.
- 409 5. Noubiap JJ, Agbor VN, Ndoadoumgue AL, et al. Epidemiology of pericardial diseases in  
410 Africa: a systematic scoping review. *Heart* 2019;105(3):180-88.
- 411 6. Mayosi BM, Wiysonge CS, Ntsekhe M, et al. Mortality in patients treated for tuberculous  
412 pericarditis in sub-Saharan Africa. *S Afr Med J* 2008;98(1):36-40.
- 413 7. Somboro AM, Diallo D, Holl JL, Maiga M. The role of the microbiome in inflammation  
414 during tuberculosis. *EBioMedicine* 2021;68
- 415 8. Mori G, Morrison M, Blumenthal A. Microbiome-immune interactions in tuberculosis. *PLoS*  
416 *Pathogens* 2021;17(4):e1009377.
- 417 9. Naidoo CC, Nyawo GR, Sulaiman I, et al. Anaerobe-enriched gut microbiota predicts pro-  
418 inflammatory responses in pulmonary tuberculosis. *EBioMedicine* 2021;67:103374.
- 419 10. Naidoo CC, Nyawo GR, Wu BG, et al. The microbiome and tuberculosis: state of the art,  
420 potential applications, and defining the clinical research agenda. *Lancet Respir Med*  
421 2019;7(10):892-906. doi: 10.1016/S2213-2600(18)30501-0 [published Online First:  
422 20190322]
- 423 11. Segal LN, Clemente JC, Li Y, et al. Anaerobic Bacterial Fermentation Products Increase  
424 Tuberculosis Risk in Antiretroviral-Drug-Treated HIV Patients. *Cell host & microbe*  
425 2017;21(4):530-37 e4. doi: 10.1016/j.chom.2017.03.003
- 426 12. Du Clos TW. Function of C-reactive protein. *Annals of medicine* 2000;32(4):274-78.
- 427 13. World Health Organization. WHO consolidated guidelines on tuberculosis. Module 2:  
428 screening-systematic screening for tuberculosis disease. Geneva, Switzerland: World  
429 Health Organization 2021.
- 430 14. Ma W, Nguyen LH, Song M, et al. Dietary fiber intake, the gut microbiome, and chronic  
431 systemic inflammation in a cohort of adult men. *Genome medicine* 2021;13(1):102.

- 432 15. Furet J-P, Kong L-C, Tap J, et al. Differential adaptation of human gut microbiota to  
433 bariatric surgery–induced weight loss: links with metabolic and low-grade inflammation  
434 markers. *Diabetes* 2010;59(12):3049-57.
- 435 16. Rajkumar H, Mahmood N, Kumar M, et al. Effect of probiotic (VSL# 3) and omega-3 on  
436 lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight  
437 adults: a randomized, controlled trial. *Mediators Inflamm* 2014;2014
- 438 17. Petakh P, Kobyljak N, Kamyshnyi A. Gut microbiota in patients with COVID-19 and type  
439 2 diabetes: A culture-based method. *Frontiers in Cellular and Infection Microbiology*  
440 2023;13:108.
- 441 18. Nyawo GR, Naidoo CC, Wu B, et al. More than Mycobacterium tuberculosis: site-of-  
442 disease microbial communities, and their functional and clinical profiles in tuberculous  
443 lymphadenitis. *Thorax* 2023;78(3):297-308.
- 444 19. Reuter H, Burgess L, van Vuuren W, Doubell A. Diagnosing tuberculous pericarditis.  
445 *QJM: An International Journal of Medicine* 2006;99(12):827-39. doi:  
446 10.1093/qjmed/hcl123
- 447 20. Bolyen E, Rideout JR, Dillon MR, et al. Reproducible, interactive, scalable and extensible  
448 microbiome data science using QIIME 2. *Nature biotechnology* 2019;37(8):852-57.
- 449 21. Callahan BJ, McMurdie PJ, Rosen MJ, et al. DADA2: high-resolution sample inference  
450 from Illumina amplicon data. *Nature methods* 2016;13(7):581-83.
- 451 22. McDonald D, Price MN, Goodrich J, et al. An improved Greengenes taxonomy with  
452 explicit ranks for ecological and evolutionary analyses of bacteria and archaea. *The ISME*  
453 *journal* 2012;6(3):610.
- 454 23. Dixon P. VEGAN, a package of R functions for community ecology. *Journal of*  
455 *Vegetation Science* 2003;14(6):927-30.
- 456 24. McMurdie PJ, Holmes S. Waste not, want not: why rarefying microbiome data is  
457 inadmissible. *PLoS computational biology* 2014;10(4)
- 458 25. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false  
459 discovery rate controlling procedures. *Bioinformatics* 2003;19(3):368-75.

- 460 26. Douglas GM, Maffei VJ, Zaneveld J, et al. PICRUSt2: An improved and customizable  
461 approach for metagenome inference. *BioRxiv* 2020:672295.
- 462 27. Caspi R, Altman T, Billington R, et al. The MetaCyc database of metabolic pathways and  
463 enzymes and the BioCyc collection of Pathway/Genome Databases. *Nucleic Acids Res*  
464 2014;42(D1):D459-D71.
- 465 28. Bu K, Wallach DS, Wilson Z, et al. Identifying correlations driven by influential  
466 observations in large datasets. *Briefings in Bioinformatics* 2022;23(1):bbab482.
- 467 29. Estaki M, Jiang L, Bokulich NA, et al. QIIME 2 Enables Comprehensive End-to-End  
468 Analysis of Diverse Microbiome Data and Comparative Studies with Publicly Available  
469 Data. *Current protocols in bioinformatics* 2020;70(1):e100.
- 470 30. Seumois G, Zapardiel-Gonzalo J, White B, et al. Transcriptional profiling of Th2 cells  
471 identifies pathogenic features associated with asthma. *The Journal of Immunology*  
472 2016;197(2):655-64.
- 473 31. Kandi V, Palange P, Vaish R, et al. Emerging bacterial infection: identification and  
474 clinical significance of *Kocuria* species. *Cureus* 2016;8(8)
- 475 32. Campbell IM, Congdon M, Capucilli PS, Fox WW. A Not So Common Infection in an  
476 Extremely Low-Birth-Weight Infant. *Clinical Pediatrics* 2020;59(11):1040-42.
- 477 33. Lokesh D, Parkesh R, Kammara R. *Bifidobacterium adolescentis* is intrinsically resistant  
478 to antitubercular drugs. *Scientific reports* 2018;8(1):11897.
- 479 34. Baral T, Kurian SJ, Thomas L, et al. Impact of tuberculosis disease on human gut  
480 microbiota: a systematic review. *Expert Review of Anti-infective Therapy* 2023(just-  
481 accepted)
- 482 35. Khaliq A, Ravindran R, Afzal S, et al. Gut microbiome dysbiosis and correlation with  
483 blood biomarkers in active-tuberculosis in endemic setting. *PloS one*  
484 2021;16(1):e0245534.
- 485 36. Wang Y, Deng Y, Liu N, et al. Alterations in the Gut Microbiome of Individuals With  
486 Tuberculosis of Different Disease States. *Frontiers in Cellular and Infection Microbiology*  
487 2022:328.

- 488 37. Esaiassen E, Hjerde E, Cavanagh JP, et al. Bifidobacterium bacteremia: clinical  
489 characteristics and a genomic approach to assess pathogenicity. *Journal of clinical*  
490 *microbiology* 2017;55(7):2234-48.
- 491 38. Nyawo GG, Naidoo CC, Wu B, et al. More than Mycobacterium tuberculosis: specific  
492 site-of-disease microbial communities, functional capacities, and their distinct clinical  
493 profiles in tuberculous lymphadenitis. *bioRxiv* 2022
- 494 39. Schillinger U, Endo A. Minor genera of the Carnobacteriaceae: Allofustis, Alloiococcus,  
495 Atopobacter, Atopococcus, Atopostipes, Bavariococcus, Desemzia, Dolosigranulum,  
496 Granulicatella, Isobaculum and Lacticigenium. *Lactic Acid Bacteria: Biodiversity and*  
497 *Taxonomy* 2014:159-70.
- 498 40. Iino T, Suzuki K-i, Harayama S. Lacticigenium naphthae gen. nov., sp. nov., a halotolerant  
499 and motile lactic acid bacterium isolated from crude oil. *International journal of systematic*  
500 *and evolutionary microbiology* 2009;59(4):775-80.
- 501 41. Billig S, Schneefeld M, Huber C, et al. Lactate oxidation facilitates growth of  
502 Mycobacterium tuberculosis in human macrophages. *Scientific reports* 2017;7(1):1-12.
- 503 42. Koh A, De Vadder F, Kovatcheva-Datchary P, Bäckhed F. From dietary fiber to host  
504 physiology: short-chain fatty acids as key bacterial metabolites. *Cell* 2016;165(6):1332-  
505 45.
- 506 43. Baxter NT, Schmidt AW, Venkataraman A, et al. Dynamics of human gut microbiota and  
507 short-chain fatty acids in response to dietary interventions with three fermentable fibers.  
508 *mBio* 2019;10(1):e02566-18.
- 509 44. Hunter RL. Pathology of post primary tuberculosis of the lung: an illustrated critical  
510 review. *Tuberculosis* 2011;91(6):497-509.
- 511 45. Light RW. Update on tuberculous pleural effusion. *Respirology* 2010;15(3):451-58.
- 512 46. Thornton CS, Mellett M, Jarand J, et al. The respiratory microbiome and nontuberculous  
513 mycobacteria: an emerging concern in human health. *European Respiratory Review*  
514 2021;30(160)

- 515 47. Wilson D, Badri M, Maartens G. Performance of serum C-reactive protein as a screening  
516 test for smear-negative tuberculosis in an ambulatory high HIV prevalence population.  
517 *PLoS ONE* 2011;6(1):e15248.
- 518 48. Sage E, Noursadeghi M, Evans H, et al. Prognostic value of C-reactive protein in HIV-  
519 infected patients with *Pneumocystis jirovecii* pneumonia. *International journal of STD &*  
520 *AIDS* 2010;21(4):288-92.
- 521 49. Boulware DR, Hullsiek KH, Puroden CE, et al. Higher levels of CRP, D-dimer, IL-6, and  
522 hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with  
523 increased risk of AIDS or death. *Journal of Infectious Diseases* 2011;203(11):1637-46.
- 524 50. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic and prognostic value of serum C-  
525 reactive protein for screening for HIV-associated tuberculosis. *The International journal of*  
526 *tuberculosis and lung disease* 2013;17(5):636-43.
- 527 51. Ciccacci F, Florida M, Bernardini R, et al. Plasma levels of CRP, neopterin and IP-10 in  
528 HIV-infected individuals with and without pulmonary tuberculosis. *Journal of Clinical*  
529 *Tuberculosis and Other Mycobacterial Diseases* 2019;16:100107.
- 530 52. Liu H, Zheng R, Wang P, et al. IL-37 confers protection against mycobacterial infection  
531 involving suppressing inflammation and modulating T cell activation. *PLoS ONE*  
532 2017;12(1):e0169922.
- 533 53. Steingart KR, Schiller I, Horne DJ, et al. Xpert® MTB/RIF assay for pulmonary  
534 tuberculosis and rifampicin resistance in adults. *Cochrane database of systematic*  
535 *reviews* 2014(1)
- 536 54. Yoon C, Semitala FC, Atuhumuza E, et al. Point-of-care C-reactive protein-based  
537 tuberculosis screening for people living with HIV: a diagnostic accuracy study. *The Lancet*  
538 *Infectious Diseases* 2017;17(12):1285-92.
- 539 55. Rogers GB, Zain NMM, Bruce KD, et al. A novel microbiota stratification system predicts  
540 future exacerbations in bronchiectasis. *Annals of the American Thoracic Society*  
541 2014;11(4):496-503.

542 56. Richardson H, Dicker AJ, Barclay H, Chalmers JD. The microbiome in bronchiectasis.

543 *European Respiratory Review* 2019;28(153)

544

545 **Data availability**

546 Data and code will be made available upon publication. Other supporting data are available

547 from the corresponding author (GT) on reasonable request.

548 **Table 1: Demographic and clinical characteristics of people with presumptive TB**  
 549 **pericarditis. dTBs were more likely to have HIV, cough, weigh less, be using non-TB**  
 550 **medications and, in PF, have lower albumin concentrations and higher ADA, LDH, and**  
 551 **uIFN- $\gamma$  concentrations than nTBs. pTBs were more likely to have HIV, previous TB,**  
 552 **more self-reported symptoms, have lower albumin concentration, and have higher**  
 553 **ADA and uIFN- $\gamma$  fluid concentration, than nTBs. dTBs were less likely to already be on**  
 554 **treatment at recruitment (< 2 weeks) compared to pTBs. Data are n/N (%) or median**  
 555 **(IQR).**

	People with presumptive TB				<i>p-value</i>		
	Total (n=139)	dTB (n=91)	pTB (n=25)	nTB (n=23)	dTB vs. pTB	dTB vs. nTB	pTB vs. nTB
Age, years	37 (31, 48)	40 (31, 48)	34 (31, 46)	37 (31, 58)	0.910	0.563	0.485
Sex (Female)	59/139 (42)	37/91 (41)	10/25 (40)	12/23 (52)	>0.999	0.450	0.580
Current tobacco smoker	30/138 (22)	17/90 (19)	6/25 (24)	7/23 (30)	0.780	0.360	0.860
Previous tobacco smoker	29/108 (27)	19/73 (26)	7/19 (37)	3/16 (19)	0.370	0.950	0.420
Clinical characteristics:							
HIV	75/139 (54)	53/91 (58)	20/25 (80)	2/23 (9)	<b>0.046</b>	<b>&lt;0.0001</b>	<b>&lt;0.0001</b>
On ART	26/73 (37)	18/53 (34)	7/18 (39)	1/2 (50)	0.930	>0.999	>0.999
CD4 count, cells/ $\mu$ l	158 (54, 319)	151 (49, 328)	208 (97, 339)	106 (36, 176)	>0.999	>0.999	0.971
Previous TB	31/136 (23)	21/88 (24)	9/25 (36)	1/23 (4)	0.339	0.072	<b>0.019</b>
Self-reported symptoms:							
Cough	76/132 (58)	52/85 (61)	16/24 (67)	8/23 (35)	0.801	<b>0.043</b>	0.058
Fever	52/131 (40)	35/85 (41)	12/23 (52)	5/23 (22)	0.480	0.142	0.067
Night sweats	68/133 (51)	45/86 (52)	15/24 (63)	8/23 (35)	0.510	0.210	0.110
Weight loss	85/134 (63)	60/87 (69)	17/24 (71)	8/23 (35)	>0.999	<b>0.006</b>	<b>0.029</b>
Chest X-ray results:							
Cardiomegaly	93/139 (67)	61/91 (67)	17/25 (68)	15/23 (65)	>0.999	>0.999	>0.999
Pulmonary infiltrates	31/139 (22)	23/91 (25)	4/25 (16)	4/23 (17)	0.480	0.600	>0.999
Hilar lymphadenopathy	11/139 (8)	7/91 (8)	2/25 (8)	2/23 (9)	>0.999	>0.999	>0.999
Miliary pattern	7/139 (5)	6/91 (7)	1/25 (4)	0/23 (0)	0.990	0.460	>0.999
Pleural effusion	88/139 (63)	60/91 (66)	16/25 (64)	12/23 (52)	>0.999	0.330	0.590
Pericardial tamponade	47/127 (37)	29/81 (36)	9/23 (39)	9/23 (39)	0.960	0.960	>0.999
Treatment history:							
Current TB treatment (<2 weeks)	21/139 (15)	12/91 (13)	9/25 (36)	0/23 (0)	<b>0.020</b>	0.144	<b>0.005</b>
No TB treatment	118/139 (85)	79/91 (87)	16/25 (64)	23/23 (100)	<b>0.020</b>	0.144	<b>0.005</b>
Other medications	58/129 (45)	33/83 (40)	9/23 (39)	16/23 (70)	>0.999	<b>0.210</b>	0.076
Non-TB antibiotic use within 1 year	21/125 (17)	12/80 (15)	7/24 (29)	2/17 (12)	0.200	>0.999	0.350
Current non-TB antibiotic use	17/21 (81)	10/12 (83)	5/7 (71)	2/2 (100)	0.980	>0.999	>0.999
Total volume aspirated (mL)	700 (500, 1000)	670 (500, 915)	720 (500, 1000)	750 (400, 1050)	>0.999	>0.999	>0.999
Fluid cytochemistry:							
ADA (U/L)	48 (26, 67)	51 (34, 68)	50 (38, 65)	16 (11, 33)	>0.999	<b>0.001</b>	<b>0.016</b>
Protein (g/L)	58 (50, 65)	58 (49, 64)	61 (55, 67)	60 (50, 64)	>0.999	>0.999	>0.999
LDH (g/L)	696 (424, 1440)	840 (451, 1440)	645 (541, 1490)	408 (181, 842)	>0.999	<b>0.016</b>	0.132



Albumin (U/L)	22 (16, 26)	21 (16, 25)	23 (19, 26)	28 (25, 30)	>0.999	<b>0.010</b>	0.126
uIFN- $\gamma$ (pg/mL)	803 (3, 2510)	1150 (165, 2590)	885 (4, 2810)	28 (0, 5)	>0.999	<b>&lt;0.0001</b>	<b>&lt;0.0001</b>
Blood CRP (mg/L)*	125 (71, 177)	137 (75, 176)	136 (93, 202)	96 (45, 174)	>0.999	>0.999	>0.999
Mortality	24 (18)	14/88 (16)	4/24 (17)	6/22 (27)	>0.999	0.350	0.610

556 \*For CRP, paired samples were available from 112/139 participants (72/91 dTB; 20/25 pTB and 20/23 nTB). Missing data:

557 Current tobacco smoker (n=1), Previous tobacco smoker (n=31), ART status (n=2), Previous TB (n=3), Self-reported symptoms

558 (n=8), Other medications (n=10), Non-TB antibiotic use within 1 year (n=14). Bold indicates statistical significance (P < 0.05).

559 Abbreviations: ADA: adenosine deaminase; ART: antiretroviral therapy; CRP: C-reactive protein; dTB: definite tuberculous

560 pericarditis; IQR: interquartile range; LDH: lactate dehydrogenase; nTB: non-tuberculous pericarditis; pTB: probable

561 tuberculous pericarditis; TB: tuberculosis; TBP: tuberculous pericarditis; and uIFN- $\gamma$ : unstimulated interferon gamma

562 **Table 2: CRP levels do not affect microbiome  $\alpha$ -diversity, but influence  $\beta$ -diversity in**  
 563 **people with presumptive TBP.  $\alpha$ -diversity remained consistent regardless of CRP**  
 564 **concentration, while significant differences in  $\beta$ -diversity were observed, indicating**  
 565 **distinct microbial compositions between the two groups.**

High vs. low CRP	Overall (n=139)			dTb (n=91)			pTb (n=25)			nTb (n=23)		
	$\alpha$ -diversity	$\beta$ -diversity		$\alpha$ -diversity	$\beta$ -diversity		$\alpha$ -diversity	$\beta$ -diversity		$\alpha$ -diversity	$\beta$ -diversity	
		<i>p</i> -value	<i>R</i> <sup>2</sup> value		<i>p</i> -value	<i>R</i> <sup>2</sup> value		<i>p</i> -value	<i>R</i> <sup>2</sup> value		<i>p</i> -value	<i>R</i> <sup>2</sup> value
All participants	0.982	<b>0.015</b>	0.02723	0.982	<b>0.013</b>	0.02723	0.2265	0.527	0.0461	0.5967	0.3333	0.04407
Within HIV-positives	0.8932	0.059	0.02537	0.5028	0.05	0.03891	0.6744	0.826	0.04857	0.3173	-	-
Within HIV-negatives	0.1432	<b>0.526</b>	0.01987	0.2282	0.719	0.03419	0.1213	<b>0.3333</b>	<b>0.36901</b>	0.6911	0.668	0.04903

Bold indicates statistical significance ( $P < 0.05$ ). Abbreviations: CRP: C-reactive protein; dTb: definite tuberculous pericarditis; nTb: non-tuberculous pericarditis; pTb: probable tuberculous pericarditis; Tb: tuberculosis.

566 **Figure legends**

567

568 **Figure 1: Study flow chart.** Pericardial fluid, skin and background controls were collected  
569 from 140 presumptive TBP people. dTBs: definite tuberculous pericarditis; nTBs: non-  
570 tuberculous pericarditis; pTBs: probable tuberculous pericarditis; Smear: Smear microscopy;  
571 MGIT960 Culture: Mycobacteria Growth Indicator Tube 960 liquid culture; Xpert: Xpert  
572 MTB/RIF; Ultra: Xpert MTB/RIF Ultra.

573

574 **Figure 2: dTBs have a distinct microbiome enriched in *Mycobacterium* and other**  
575 **potential opportunistic pathogens. (A)** Although  $\alpha$ -diversity, which measures species  
576 diversity, was similar across the three groups, **(B)**  $\beta$ -diversity, which measures differences in  
577 microbial composition, differed significantly between PF microbiota of pTBs vs. dTBs and  
578 pTBs vs. nTBs. **(C)** dTBs vs. nTBs were *Mycobacterium*-, *Lacticigenium*- and *Kocuria*-  
579 enriched, and *Streptococcus*-depleted. **(D)** dTBs vs. pTBs were *Mycobacterium*-,  
580 *Lacticigenium*-, and *Caulobacter*-enriched and *Streptococcus*-depleted. **(E)** pTBs vs. nTBs  
581 were *Novosphingobium*- and *Streptococcus*-enriched (red dotted line represents adjusted  $p$ -  
582 value=0.2; circle size represents relative abundance; taxa identified as possible  
583 contaminants are shown in grey). **(F)** Genus-level average relative abundances of top taxa  
584 differentiating between TB groups. dTB: definite tuberculous pericarditis; nTB: non-  
585 tuberculous pericarditis; PF: pericardial fluid; pTB: probable tuberculous pericarditis; TB:  
586 tuberculosis; TBP: tuberculous pericarditis.

587

588 **Figure 3: *Bifidobacterium* enrichment is associated with *Mycobacterium* and HIV**  
589 **positivity in TBP.** In PLHIV, **(A)**  $\alpha$ -diversity did not differ by TB status, **(B)** however,  $\beta$ -  
590 diversity did, **(C)** where HIV-positive dTBs were *Mycobacterium*-, *Bifidobacterium*-, and  
591 *Leptothrix*-enriched, and *Streptococcus*-depleted compared to HIV-positive pTBs. In people  
592 without HIV, both **(D)**  $\alpha$ -diversity and **(F)**  $\beta$ -diversity did not differ by TB status, and HIV-  
593 negative dTBs were *Mycobacterium*, *Caulobacter*, and *Weeksellia*-enriched, and

594 *Streptococcus*-depleted compared to HIV-negative pTBs (red dotted line represents adjusted  
595  $p$ -value=0.2; circle size represents relative abundance; taxa identified as possible  
596 contaminants are shown in grey). dTB: definite tuberculous pericarditis; HIV+: HIV-positive;  
597 HIV-: HIV-negative; nTB: non- tuberculous pericarditis; PF: pericardial fluid; pTB: probable  
598 tuberculous pericarditis; TB: tuberculosis; TBP: tuberculous pericarditis

599

600 **Figure 4: Correlations between imaging and clinical characteristics and the PF**

601 **microbiota.** Pulmonary infiltrates (PI) and pleural effusions (PE) are associated with PF  
602 microbiome. Compared to patients without PI, **(A)** presumptive TBPs with a PI were  
603 *Mycobacterium*-enriched and *Lactigenium*- and *Streptococcus*-depleted, whilst **(B)**  
604 compared to patients without PE, presumptive TBP people with PE were *Streptococcus*- and  
605 *Pseudomonas*-enriched, and *Brachymonas*-depleted (red dotted line represents adjusted  $p$ -  
606 value=0.2; circle size represents relative abundance; taxa identified as possible  
607 contaminants are shown in grey). dTB: definite tuberculous pericarditis; PF: pericardial  
608 fluid; PE: pleural effusions; PI: pulmonary infiltrates; pTB: probable tuberculous pericarditis;  
609 TB: tuberculosis; TBP: tuberculous pericarditis

610

611 **Figure 5: Inferred functional content shows enrichment of SCFA metabolic pathways**

612 **in the PF of TBP.** PF in dTBs infer a distinct functional capacity, including an enrichment of  
613 pathways associated with the production of short-chain fatty acids (SCFAs), aromatic  
614 compound degradation, and mycobacterial metabolism vs. nTBs (red dotted line represents  
615 adjusted  $p$ -value=0.05; circle size represents relative abundance; pathways of interest are  
616 bolded). dTB: definite tuberculous pericarditis; PF: pericardial fluid; nTB: non-tuberculous  
617 pericarditis; TB: tuberculosis; TBP: tuberculous pericarditis; SCFA: short chain fatty acids.


618

619 **Figure 6: Microbial composition differs in presumptive TBP people with high vs low**

620 **CRP.**

621 **A)** CRP levels are similar in dTBs vs. pTBs vs. nTBs. **B)** Mycobacterial reads do not  
622 correlate with CRP levels;  $r_s$  represents the Spearman's Rho coefficient for the correlation of  
623 mycobacterial reads with CRP. People with high CRP levels have similar **C)** *Mycobacterium*  
624 reads and **D)**  $\alpha$ -diversity in their pericardial fluid compared to people with low CRP levels  
625 (solid circles: dTB; empty squares: pTB; empty circles: nTB). **E)**  $\beta$ -diversity differs between  
626 people with high vs low CRP. **F)** *Pseudomonas* is depleted in people with high vs low CRP.  
627 Discriminatory taxa appear above the threshold (red dotted line, FDR=0.2); circle size  
628 represents relative abundance. CI, Confidence interval; CRP,  $\square$ C-reactive protein; dTB:  
629 definite-TBP; FDR, false discovery rate; nTBP, non-TBP; PERMANOVA, permutational  
630 multivariate analysis of variance; pTB: probable-TBP; TBP: tuberculous pericarditis.

Figure 1.



Samples from 140 people were randomly rarefied to a depth of 1821 features and one sample with insufficient depth was excluded, leaving samples from 139 people.

Abbreviations: ART: antiretroviral therapy; dTB: definite tuberculous pericarditis; MGIT960 culture: mycobacteria growth indicator tube 960 liquid culture; nTB: non-tuberculous pericarditis; pTB: probable tuberculous pericarditis; Smear: Smear microscopy; Ultra: Xpert MTB/RIF Ultra; Xpert: Xpert MTB/RIF; TB: tuberculosis; TBP: tuberculous pericarditis.

Figure 2.




Figure 3.






Figure 4.




Figure 5.




Figure 6.

